Elanco logo with Financial News caption
8 May 2024

Elanco Animal Health Reports First Quarter 2024 Results


Post by: Colleen Parr Dekker

  • First Quarter 2024 Financial Results
    • Revenue of $1,205 million
    • Reported Net income of $32 million, Adjusted Net income of $167 million
    • Adjusted EBITDA of $294 million, or 24.4% of Revenue
    • Reported EPS of $0.06, Adjusted EPS of $0.34
    • Net leverage ratio of 6.1x Adjusted EBITDA
    • Year over year growth rates are meaningfully impacted by a shift in customer purchasing related to the ERP Blackout in 2023, with an estimated $90 to $110 million of revenue shift from the second quarter of 2023 into the first quarter of 2023
  • Updating full year 2024 financial guidance to reflect first quarter outperformance offset by expected unfavorable impact of foreign exchange rates:
    • Revenue of $4,460 to $4,515 million, constant currency growth improves to 2% to 3%
    • Reported Net Loss of $(3) to $(45) million; Reported EPS of $(0.01) to $(0.09)
    • Adjusted EBITDA of $960 to $1,000 million; Adjusted EPS of $0.88 to $0.96

GREENFIELD, Ind (May 8, 2024) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2024, provided guidance for the second quarter of 2024, and updated guidance for the full year 2024.

To view full Press Release, click here.

Investor Contact

Kathryn Grissom



Media Contact

Colleen Parr Dekker




    Connect with Elanco

    Country selector

    Elanco's Healthy Purpose, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2024 Elanco or its affiliates.